Managing Patients on Oral Oncolytics

Conference Correspondent  - Conference Correspondent, ASH
Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ

Ali McBride provides an overview of the role of the pharmacist and the importance of working with a broad team of healthcare providers in managing patients on oral oncolytics.

That's an excellent question. Right now, I work with a team of advanced practitioners, physicians, healthcare providers, and also finance to actually obtain a drug therapy for patients looking at dose adjustments, and also looking at compliance, or adherence for certain type of therapies.

We actually have a multi‑factorial role with multi‑disciplinary based evaluations for patients on oral oncolytics at this point. We have multiple roles, would be a better word for this. Making sure the patient is actually getting the drug which oftentimes for any first dose drug in the oral oncolytic, some patients may not even pick up that prescription, or even work on that prescription for several weeks later.

They're not even starting that therapy until a later time point. We have difficulties there as well. In addition, we also make sure the patient is getting the drug therapy. Sometimes, finance is a barrier.

Out of pocket expense has become an issue. We have seen a lot of work in regards to oral chemotherapy parity in which we're making sure the patients can actually afford those copays. Based on estate base legislation issues at each state across the country is also a federal act that's still in the pipeline right now.

We have numerous types of focuses. It may depend on the patient, it may depend on the physician, and what they want as well, but the goal is to make sure the patient has access to therapies, and they're adherent to therapies to make sure they maximize their outcomes with their treatment.

Related Items
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Subcutaneous Romiplostim Increased Platelet Response in Children with ITP
Conference Correspondent  published on December 27, 2017 in ASH
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Last modified: December 5, 2017